Company / Operating Income
Monopar Therapeutics Operating Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$16.7M
FY2025
5-year range
-$16.7M / -$4.3M
FY2021-FY2025
Trend
-89.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 6 years, ranging from -$17M in FY2025 to -$1M in FY2017.
Based on SEC 10-K filings.
-$17M in FY2025.
Declined from -$11M to -$17M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 89.2% year-over-year.
- Peak operating income was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 19.82 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$16.7M | -89.2% |
| FY2024 | -$8.8M | +16.2% |
| FY2023 | -$10.5M | -143.7% |
| FY2019 | -$4.3M | +74.0% |
| FY2018 | -$16.6M | -1291.9% |
| FY2017 | -$1.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026